We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Various Factors Influence Cardiac Troponin Concentrations

By LabMedica International staff writers
Posted on 14 Sep 2017
Cardiovascular diseases are the second most common cause of death in Japan, and the number of new cases is continuously growing. More...
Among the cardiovascular diseases, one-third is attributed to ischemic heart diseases including acute myocardial infarction (AMI).

Cardiac troponin I is a protein that is specifically expressed in cardiomyocytes and is eluted in the blood when cardiomyocytes are injured such as by ischemia. Due to its specificity, cardiac troponin I has become one of the most reliable biomarkers for the diagnosis of AMI.

Scientists at the Japanese Red Cross Medical Center (Tokyo, Japan) and their colleagues enrolled a total of 698 apparently healthy individuals (385 females and 313 males) between the ages of 23 and 86 who visited the Medical Center for a health checkup from January through April in 2014 were included in this study.

The team performed routine biochemistry tests on a BioMajesty JCA-BM6070 clinical biochemistry analyzer that included the assays for aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transferase (GGT), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), creatinine (Cre), hemoglobin A1c (HbA1c), and lactate dehydrogenase (LDH). Serum samples were used for the measurement of all the assays except for HbA1c, which was measured with whole-blood samples.

The Abbott Laboratories’ STAT high-sensitive troponin I (hsTnI) was performed for the measurement of cardiac troponin I on Architect i2000. The limit of detection (LoD) of the assay was 1.9 pg/mL, the lowest concentration where 10% coefficient of variation (CV) was supported was 4.7 pg/mL and the overall 99th percentile was 26.2 pg/mL. The CardioPhase high-sensitive C-reactive protein (hsCRP) tests were performed for the measurement of CRP. The limit of detection (LoD) of the assay was 0.175 mg/L, the CV was 7.6% at 0.410 mg/L and the reference value was 3 mg/L.

The scientists found that the 99th percentile of the hsTnI in the overall population was 22.5 pg/mL, 17.7 pg/mL for females and 30.6 pg/mL for males. The median of the hsTnI in the overall population was 3.2 pg/mL, 2.6 pg/mL for females and 4.0 pg/mL for males. The age and gender had a significant influence on these values. The troponin I level also showed significant associations with the body mass index (BMI), the gamma glutamyl transferase (GGT), lactate dehydrogenase (LDH), estimated glomerular filtration rate (eGFR), and cardiac abnormalities by electrocardiography (ECG), but not with the high-sensitive C-reactive protein (hsCRP) level.

The authors concluded that the 99th percentiles of the troponin I measured in the general population in Japan were comparable as the ones derived in the USA, Germany, and Singapore. The troponin I level was dependent on the gender, age, BMI, and cardiac abnormalities found by electrocardiogram (ECG) but not by the hsCRP level. The study was published on August 1, 2017, in the Journal of Clinical Laboratory Analysis.

Related Links:
Japanese Red Cross Medical Center


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.